View Older Stories View More Recent Stories

Jul 23, 2019 04:10PM Form 4 AVROBIO, Inc. For: Jul 19 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Jul 22, 2019 08:00AM Disarm Therapeutics Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer
Jul 15, 2019 08:00AM Kymera Therapeutics Announces Leadership Transitions
Jun 28, 2019 08:30AM Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors
Jun 25, 2019 06:06PM Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 25, 2019 08:00AM Generation Bio Appoints Katherine Fitzgerald, Ph.D., to its Scientific Advisory Board
Jun 19, 2019 06:32PM Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 6, 2019 01:26PM Harvard Business School Announces $10 Million Gift Renewal from the Blavatnik Family Foundation and Introduces 2019-2020 Blavatnik Fellows in Life Science Entrepreneurship
May 31, 2019 08:00AM Generation Bio to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 07:00AM Cadent Therapeutics Announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia
May 28, 2019 07:00AM Cadent Therapeutics to Present at the Jefferies Healthcare Conference
May 23, 2019 07:00AM Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression
May 13, 2019 05:28PM Form 13F-NT ATLAS VENTURE FUND VI For: Mar 31
May 13, 2019 04:10PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2019 04:09PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2019 03:48PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 13, 2019 01:44PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 8, 2019 07:00AM IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
May 7, 2019 08:00AM Kyn Therapeutics Strengthens Leadership Team with Key Appointments
May 7, 2019 08:00AM Science2Startup Symposium Convened Close to 300 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections to Advance Scientific Innovation and Entre
Apr 18, 2019 08:00AM Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
Apr 18, 2019 07:00AM Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer
Apr 12, 2019 07:00AM Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
Apr 3, 2019 06:30AM Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
Apr 1, 2019 05:00AM Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million
Apr 1, 2019 02:28AM Novartis to pay $310 million for assets from inflammation specialist IFM
Apr 1, 2019 01:15AM Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Mar 28, 2019 07:00AM IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427
Mar 22, 2019 05:04PM Form 4 Magenta Therapeutics, For: Mar 20 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Feb 14, 2019 05:38PM Form 4 Replimune Group, Inc. For: Feb 12 Filed by: Atlas Venture Fund X, L.P.
Feb 14, 2019 06:00AM Cadent Therapeutics Appoints Jodie Morrison as Chief Executive Officer
Feb 13, 2019 04:27PM Form SC 13G Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 13, 2019 04:27PM Form SC 13G AVROBIO, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 13, 2019 04:27PM Form SC 13G Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 12, 2019 02:59PM Form 13F-NT ATLAS VENTURE FUND VI For: Dec 31
Feb 12, 2019 02:58PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 12, 2019 02:58PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 11, 2019 11:24AM Form SC 13G Carbon Black, Inc. Filed by: Atlas Venture Associates VI, L.P.
Feb 8, 2019 01:51PM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Feb 8, 2019 06:20AM Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G/A Intellia Therapeutics, Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G Unum Therapeutics Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G Translate Bio, Inc. Filed by: Atlas Venture Fund VIII, L.P.
Feb 8, 2019 06:20AM Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
Feb 6, 2019 03:45PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 4, 2019 07:00AM Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer
Jan 28, 2019 08:00AM Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Jan 23, 2019 07:00AM Schrödinger Appoints Veteran Biotech Industry Leader Dr. Rosana Kapeller to Board of Directors
Jan 18, 2019 07:02AM Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene (CELG)
View More Recent Stories View Older Stories